Royal Marsden NHS Foundation Trust
348
63
79
110
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
4.6%
16 terminated/withdrawn out of 348 trials
87.3%
+0.7% vs industry average
3%
12 trials in Phase 3/4
18%
20 of 110 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (348)
A Phase II Trial of Tebentafusp in HLA-A*02:01 Positive Patients With Advanced Clear Cell Sarcoma
Role: collaborator
Evaluation of Seismocardiography(SCG) for Assessing Fitness and Predicting Outcomes in Oesophageal Cancer Surgery
Role: collaborator
Investigating SX-682 in Combination With Apalutamide in Metastatic Castration-resistant Prostate Cancer
Role: collaborator
Investigating the Combination of Bexmarilimab and Nivolumab in Solid Tumours, Melanoma and NSCLC
Role: collaborator
PAveMenT: Palbociclib and Avelumab in Metastatic AR+ Triple Negative Breast Cancer
Role: lead
Zimberelimab Anti-PD1 +/- Domvanalimab in Resectable Mmrd Gastric Cancer
Role: lead
5G-EMERALD: Amivantamab in Malignant Brain Tumours
Role: collaborator
UK Genetic Prostate Cancer Study: Epidemiology and Molecular Genetics Studies
Role: collaborator
Digital Body Mindset Intervention for Young Cancer Survivors
Role: collaborator
Patient and Provider Perspectives on Genetic Risk Profiling
Role: lead
Understanding the Genetic and Biological Factors That Influence Cancer Treatment Response and Resistance in Patients With Advanced Solid Tumours Through Sample Analysis
Role: collaborator
SBRT With Immunotherapy in Early Stage Non-small Cell Lung Cancer: Tolerability and Lung Effects
Role: lead
SBRT Alone or Followed by Niraparib for Oligometastases or Oligoprogression in Ovarian Cancer Following PARPi Therapy
Role: collaborator
A Phase-II Clinical Trial of Radiotherapy to the Coeliac Plexus to Help Pain in Advanced Pancreatic Cancer
Role: lead
DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial) - Master Screening Protocol
Role: collaborator
A Study of Short-course Hypofractionated Online-adaptive Radiotherapy for the Post-operative Treatment of Endometrial Cancer: Tolerability and Feasibility
Role: lead
Clinical Utility of ctDNA in Detecting Resistance Mechanisms and Delivering Precision Medicine to Cancer Patients
Role: lead
An AI Platform Integrating Imaging Data and Models, Supporting Precision Care Through Prostate Cancer's Continuum
Role: collaborator
A Study of Pembrolizumab And Platinum With Radiotherapy in Cervix Cancer
Role: lead
Targeted Radiotherapy in Androgen-suppressed Prostate Cancer Patients.
Role: lead